Story thread · 2 reports / 2 sources

FDA expands Pluvicto label, making it available to most metastatic prostate cancer patients

endpts.com · 8dShare

The FDA approved Novartis’ radiopharma drug Pluvicto for use alongside hormone therapy, making the drug available to many more patients. The approval nearly doubles the eligible patient population for Pluvicto, according to a Novartis

First report: Pluvicto Approved Earlier in Metastatic Prostate Cancer — medscape.com, 8d